AI in Cervical Cancer Screening

Cervical cancer screening uses tests to identify risk of precancer or cancer before symptoms develop. AI research has examined digital cytology slides, colposcopy images and photographs used with visual inspection after acetic acid (VIA). A model can classify cells, mark a region or help prioritize a slide for review. Those tasks are different from confirming cancer: diagnosis may require colposcopy, biopsy and pathology, and screening decisions follow local clinical guidance. The World Health Organization recommends HPV DNA testing as the primary screening method rather than VIA or cytology in its global screening-and-treatment guidance, while allowing different triage pathways based on program context. That matters when describing AI: a promising Pap-image classifier does not establish that cytology should replace HPV testing, and an AI tool for VIA does not by itself become a validated population screening program. Studies have shown research promise, but they vary in image sources, reference standards and populations. One diagnostic study of an AI system for visual inspection compared an algorithm with health workers and experts on 83 existing images; the result was a small image-set evaluation, not proof of effectiveness at scale. A larger cytology study evaluated an AI system against cytotechnologists across several hospitals, but its findings still need interpretation in the study’s clinical setting. Before use, health systems need evidence on image quality, false results, external performance, referral follow-through and equity. A false negative can delay needed care; a false positive can lead to anxiety and additional procedures. Human reviewers should understand what the model was trained to detect and what it does not evaluate. AI might support quality control or triage, but screening policy, confirmatory testing and treatment remain clinical and public-health responsibilities.